Evidence map›Paper›PMID 32779152›Full record

ArticleHuman cell2020

Mild acidity likely accelerates the physiological matriptase autoactivation process: a comparative study between spontaneous and acid-induced matriptase zymogen activation.

Bailing Jia, Hamishi A Thompson, Robert B Barndt, Yi-Lin Chiu, Mon-Juan Lee, See-Chi Lee, Jehng-Kang Wang, Hung-Jen Tang, Chen-Yong Lin, Michael D Johnson

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Human cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Bailing JiaDepartment of Gastroenterology, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Hamishi A ThompsonLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
Robert B BarndtLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
Yi-Lin ChiuLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
Mon-Juan LeeLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
See-Chi LeeLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
Jehng-Kang WangDepartment of Biochemistry National Defense Medical Center, Taipei, 114, Taiwan.
Hung-Jen TangSection of Infectious Diseases, Internal Medicine, Chi-Mei Medical Center, No.901, Chung-Hwa Rd. Yung-Kang Dist., Tainan City, 71004, Taiwan, ROC. 8409d1@gmail.com.
Chen-Yong LinLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA. lincy@georgetown.edu.ORCID http://orcid.org/0000-0002-6391-2571
Michael D JohnsonLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA. johnsom@georgetown.edu.
Georgetown University · USChung Hwa University of Medical Technology · TWNational Defense Medical Center · TW

Funding

Mechanisms of Deregulation of Matriptase in Breast CancerR01CA123223 · NCI · GEORGETOWN UNIVERSITY · PI JOHNSON, MICHAEL D, LIN, CHEN-YONG · 2010 to 2014
$1.6M
Chi Mei Medical Center CMNDMC10705Chi Mei Medical Center CMNDMC10813Ministry of National Defense Medical Affairs Bureau, Taiwan MAB-108-079NCI NIH HHS RO1 CA 123223
6 · The paper itself

Abstract

The pathophysiological functions of matriptase, a type 2 transmembrane serine protease, rely primarily on its enzymatic activity, which is under tight control through multiple mechanisms. Among those regulatory mechanisms, the control of zymogen activation is arguably the most important. Matriptase zymogen activation not only generates the mature active enzyme but also initiates suppressive mechanisms, such as rapid inhibition by HAI-1, and matriptase shedding. These tightly coupled events allow the potent matriptase tryptic activity to fulfill its biological functions at the same time as limiting undesired hazards. Matriptase is converted to the active enzyme via a process of autoactivation, in which the activational cleavage is thought to rely on the interactions of matriptase zymogen molecules and other as yet identified proteins. Matriptase autoactivation can occur spontaneously and is rapidly followed by the formation and then shedding of matriptase-HAI-1 complexes, resulting in the presence of relatively low levels of the complex on cells. Activation can also be induced by several non-protease factors, such as the exposure of cells to a mildly acidic buffer, which rapidly causes high-level matriptase zymogen activation in almost all cell lines tested. In the current study, the structural requirements for this acid-induced zymogen activation are compared with those required for spontaneous activation through a systematic analysis of the impact of 18 different mutations in various structural domains and motifs on matriptase zymogen activation. Our study reveals that both acid-induced matriptase activation and spontaneous activation depend on the maintenance of the structural integrity of the serine protease domain, non-catalytic domains, and posttranslational modifications. The common requirements of both modes of activation suggest that acid-induced matriptase activation may function as a physiological mechanism to induce pericellular proteolysis by accelerating matriptase autoactivation.

Indexed as

Enzyme ActivationAcidsEnzyme PrecursorsHumansMutationProteinase Inhibitory Proteins, SecretoryProtein DomainsProtein Processing, Post-TranslationalSerine EndopeptidasesTumor Cells, CulturedAcidsEnzyme PrecursorsmatriptaseProteinase Inhibitory Proteins, SecretorySerine EndopeptidasesSPINT1 protein, humanAcidityMatriptaseZymogen activation

Identifiers

PMID32779152
OpenAlexW3048864039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.